Anne B. Cropp
Chief Scientific Officer, Early Access Care
Anne Cropp Pharm.D. is Chief Scientific Officer for Early Access Care, a company exclusively providing global Expanded Access/Compassionate Use services.  Anne has led the development of Expanded Access programs for small, mid, and large pharma companies based in the US, Europe, and Asia. Prior to founding Early Access Care, Anne was Vice President in the Global Product Development Group of Pfizer Inc responsible for Phase 2 and 3 Clinical Development Programs and Head of the Compassionate Access Group for Pfizer.  She is a globally recognized expert in expanded access and compassionate use and has over 25 years experience in early access programs.Â
Marjorie Zettler
Director of Clinical Science, Regor Pharmaceuticals, Inc.
Marjorie Zettler, PhD, MPH is Director of Clinical Science at Regor Pharmaceuticals, Inc., a pioneering drug discovery and clinical-stage pharmaceutical research company. An industry veteran with more than 18 years’ experience at companies in the pharma and healthcare sector including Lilly and Cardinal Health, her work has focused on clinical research, drug development, and regulatory strategy. She has published over 100 abstracts, manuscripts, and patents. Dr. Zettler received a doctorate in physiology and a bachelor’s degree (honors) in genetics from the University of Manitoba, Canada, as well as a master’s degree in public health from the University of Manchester, United Kingdom. Â
Lisa Kearns
Division of Medical Ethics, NYU Grossman School of Medicine
Awaiting bio.Â
Khrystal Davis
Founder, Texas Rare Alliance
Awaiting for bio.Â
Neena Nizar
President & Founder, The Jansens Foundation
Awaiting for bio.Â
Senior Representative 1
Available Shortly.
Christine Von Raesfeld
Founder & CEO, People with Empathy
Awaiting for bio.
Sam Lucas
Senior VP, Expanded Access Program, Durbin
Awaiting for bio.
Kim Buchanan
Associate Director Development Quality, Merck
Mrs. Buchanan is currently the Associate Director of MRL Global Development Quality supporting Global Clinical Supplies at Merck & Co. Over the past twenty-five years, she has held commercial Quality and commercial packaging operational experience. While supporting Global Clinical Supply, she has worked in Global Clinical Supply as a program manager, Global Clinical Supply Logistics Coordinator and in Global Development Quality supporting release of Clinical Supplies and process improvements. She was key to the development of the Expanded Access at her company.
Eugean Jiwanmall
Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross
Eugean Jiwanmall’s past professional experiences include basic science and clinical research. In his current role as a Senior Research Analyst for Medical Policy & Technology Evaluation at Independence Blue Cross’ Medical & Claim Payment Policy Department within Facilitated Health Networks and Medical Affairs, he has served as the subject-matter-expert, writer, reviewer, communicator, presenter, consultant, adviser/facilitator, and decision-maker for hundreds of medical policy topics and technology assessments within dozens of clinical disciplines and multiple business areas. Eugean has participated in numerous roles & capacities in a number of conferences, summits, and other national & international events etc. upon invitations. He has been invited by renowned organizations, evaluator bodies, & thinktanks etc. to be key informant on a variety of complex and challenging topics, and recognized in communications & publications for these works.
Eugean has taken and completed graduate coursework in bioethics at the University of Pennsylvania School of Medicine. He holds a bachelor’s degree in biological sciences with honors from Drexel University (minor was in business administration), a master’s degree of public health in evaluative clinical sciences from Dartmouth Medical School, and an MBA in healthcare management and economics with honors from Drexel University.
William Richard Light
Chief Scientific Officer, VirTech Bio
Trinayan Kashyap
Director, Global Expanded Access Lead and Research & Translational Development, Karyopharm Therapeutics Inc
I am currently serving as the Director of Translational Research and Global Expanded Access Lead at Karyopharm Therapeutics. I have been with Karyopharm Therapeutics for 10+ years and was involved with the discovery of the first-in-class oral selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO). Subsequently, I led the pre-clinical efforts in the discovery of the second generation SINE compound, which is currently being tested in phase 1 and 2 clinical studies. I have also been involved with clinical development programs at Karyopharm. Since 2019, I have been assigned to lead the Expanded Access Program at Karyopharm. Prior to Karyopharm, I was working at Beth Israel Deaconess Medical Center, Boston. I received by master’s degree in Biological Sciences from the University of Massachusetts, Lowell.
John Lagus
Executive Vice President, Business Development, Tanner Pharma Group
John Lagus is the Executive Vice President of Business Development for Tanner Pharma Group. John spent more than a decade at Orphan Medical where he held various roles in development, commercial, corporate development, and oversight of international. Prior to joining, John worked for 12 years at Idis (and subsequently Clinigen) with roles in commercial, operations, and general management. John has a BA in mathematics from St Olaf College and a MS in statistics from Iowa State University.
Â
Dana Dunne
Expanded Access Program Director, Tanner Pharma Group
Dana Dunne is the Expanded Access Program Director at Tanner Pharma Group. Prior to joining Tanner, Dana worked for 13+ years at mid- to large-size CROS, holding various clinical operational roles including clinical management of both local and global clinical trials. Dana has a BS in Dental Hygiene from the University of North Carolina at Chapel Hill and a Clinical Trials Research Associate (AAS) Degree from Durham Technical Community College.
Oliver White
Senior Program Manager, Tanner Pharma Group
Oliver White serves as Senior Program Manager for the Managed Access Programs (TannerMAP) division of Tanner Pharma Group. During his tenure with the company, Oliver has led the design and set-up of several Managed Access Programs for rare disease and oncology products. Oliver holds a master’s degree in chemistry from Durham University, England, and has undertaken pharmaceutical research placements at Vertex Pharmaceuticals and Université Grenoble Alpes, France.
Bionical Emas
Senior Representative
Robert Keel
Executive Vice President, Managed Access Programs, Tanner Pharma Group
Rob Keel is the Executive Vice President of Managed Access Programs (TannerMAP) and Managing Director in Switzerland for Tanner Pharma Group. He has lived and worked extensively on an international basis and feels it is a privilege to be able to help others. He has held global general management, supply chain and finance roles within the airline, agriculture, and pharmaceutical industries across the EMEA and Asia-Pacific regions. Prior to joining Tanner, Rob was part of the EMEA senior management team at AstraZeneca and held various positions at Alliance Boots (now Walgreens) and Genentech. Rob holds an Industrial Engineering and Management Sciences degree from Northwestern University and an MBA from Harvard Business School.
Senior Representative 11
Available Shortly.
Senior Representative 12
Available Shortly.
Senior Representative 13
Available Shortly.
Senior Representative 14
Available Shortly.
Senior Representative 15
Available Shortly.
Senior Representative 16
Available Shortly.
Senior Representative 17
Available Shortly.
Senior Representative 18
Available Shortly.
Senior Representative 19
Available Shortly.
Senior Representative 20
Available Shortly.
Senior Representative 21
Available Shortly.
Senior Representative 22
Available Shortly.
Senior Representative 23
Available Shortly.
Senior Representative 24
Available Shortly.
Senior Representative 25
Available Shortly.
